Files and links (1)
Published, Version of Record (VoR)CC BY-NC-ND V4.0, Open
Journal article
Breast Cancer in Systemic Lupus Erythematosus
Oncology, v 85(2), pp 117-121
01 Jan 2013
PMID: 23887245
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective: Evidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries. Methods: Information on age, SLE duration, cancer date, and histology was available. We analyzed information on histological type and performed multivariate logistic regression analyses of histological types according to age, SLE duration, and calendar year. Results: We studied 180 breast cancers in the SLE cohort. Of the 155 cases with histology information, 11 were referred to simply as 'carcinoma not otherwise specified'. In the remaining 144 breast cancers, the most common histological type was ductal carcinoma (n = 95; 66%) followed by lobular adenocarcinoma (n = 11; 8%), 15 cancers were of mixed histology, and the remaining ones were special types. In our regression analyses, the independent risk factors for lobular versus ductal carcinoma was age [odds ratio (OR) 1.07, 95% confidence interval (Cl) 1.01-1.14] and for the 'special' subtypes it was age (OR 1.06, 95% Cl 1.01-1.10) and SLE duration (OR 1.05, 95% CI 1.00-1.11). Conclusions: Generally, up to 80% of breast cancers are ductal carcinomas. Though our results are not definitive, in the breast cancers that occur in SLE, there may be a slight decrease in the ductal histological type. In our analyses, age and SLE duration were independent predictors of histological status. Copyright (C) 2013 S. Karger AG, Basel
Metrics
Details
- Title
- Breast Cancer in Systemic Lupus Erythematosus
- Creators
- B. Tessier Cloutier - McGill UniversityA. E. Clarke - McGill UniversityR. Ramsey-Goldman - Northwestern UniversityY. Wang - McGill UniversityW. Foulkes - McGill UniversityC. Gordon - University of BirminghamJ. E. Hansen - Yale UniversityE. Yelin - University of California, San FranciscoM. B. Urowitz - University of TorontoD. Gladman - Toronto Western HospitalP. R. Fortin - Université LavalD. J. Wallace - University of California, Los AngelesM. Petri - Johns Hopkins UniversityS. Manzi - Allegheny General HospitalE. M. Ginzler - SUNY Downstate Health Sciences UniversityJ. Labrecque - McGill UniversityS. Edworthy - University of CalgaryM. A. Dooley - University of North Carolina at Chapel HillJ. L. Senecal - Université de MontréalC. A. Peschken - University of ManitobaS. C. Bae - Hanyang University Seoul HospitalD. Isenberg - UCL AustraliaA. Rahman - UCL AustraliaG. Ruiz-Irastorza - Hospital de CrucesJ. G. Hanly - Dalhousie UniversityS. Jacobsen - University of CopenhagenOla Nived - Lund UniversityT. Witte - Medizinische Hochschule HannoverL. A. Criswell - University of California, San FranciscoS. G. Barr - University of CalgaryL. Dreyer - University of CopenhagenGunnar Sturfelt - Lund UniversityS. Bernatsky - McGill UniversitySLICC
- Publication Details
- Oncology, v 85(2), pp 117-121
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000323873300007
- Scopus ID
- 2-s2.0-84880396935
- Other Identifier
- 991021933908504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology